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BACKGROUND: Earlier research suggests that use of selective serotonin reuptake inhibitors (SSRIs), but not tricyclic antidepressants
(TCAs), reduces the risk of colorectal cancer (CRC).
METHODS: We conducted a population-based case–control study to investigate the association between antidepressant use and CRC
risk. Cases were diagnosed with a first primary CRC from 1991 through 2008. We selected 10 population controls matched to cases
on sex, birth year, and residence from the Danish Civil Registration System using risk-set sampling. We estimated the odds ratios
(ORs) and 95% confidence intervals (CIs) associating antidepressant use with colorectal cancer occurrence, controlling for potential
confounders.
RESULTS: The study included 9979 cases and 99790 controls. We found no notable reduction in CRC risk in ever users
(X2 prescriptions) of TCAs (OR¼0.94; 95% CI: 0.84, 1.05), SSRIs (OR¼0.97; 95% CI: 0.90, 1.05), or other antidepressants
(OR¼0.95; 95% CI: 0.83, 1.07). Associations for recent and former use of antidepressants were also near null. Intensity of
antidepressant use (number of pills divided by total duration of use), regardless of duration, was not associated with CRC risk.
CONCLUSIONS: We found no evidence that antidepressant use substantially reduces the risk of colorectal cancer.
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Antidepressants are used to treat depression, anxiety, and pain
(Alonso et al, 2004; Paulose-Ram et al, 2007). Most western
countries report at least a doubling in the prevalence of
antidepressant use over the last two decades (McManus et al,
2000; Paulose-Ram et al, 2007). Studies on the safety of
antidepressants, including beneficial side effects, are important.
Antidepressants may have chemopreventive properties against
colorectal cancer (CRC). They inhibit colorectal tumour growth in
animal models and cell lines (Arimochi and Morita, 2006;
Arimochi and Morita, 2008; Brandes et al, 1992; Steingart and
Cotterchio, 1995; Tutton and Barkla, 1982). Few population-based
studies, however, have focused specifically on CRC (Coogan et al,
2009; Haukka et al, 2010; Xu et al, 2006). A Canadian registry-
based case–control study reported a reduced risk of CRC
associated with daily selective serotonin reuptake inhibitor (SSRI)
use for 0–5 years before CRC diagnosis or control’s matched index
date (incidence rate ratio (IRR)¼0.70 (95% confidence interval
(CI)¼0.50, 0.96), but a near null association with tricyclical
antidepressant (TCA) use (IRR¼0.96 (95% CI¼0.84, 1.10; Xu
et al, 2006). A similar finding for SSRIs was reported in a US
hospital-based case–control study (Coogan et al, 2009), but not in
a Finnish registry-based cohort study (Haukka et al, 2010).
Given the high prevalence of antidepressant use and CRC in
western countries (Parkin et al, 2005), any association between
them would have significant public health implications. We
therefore conducted a large population-based case–control study
using prospectively collected prescription data to examine whether
antidepressant use is associated with reduced risk of CRC.
PATIENTS AND METHODS
We conducted this population-based case–control study among
the residents of Northern Denmark (the former counties of North
Jutland and Aarhus), where approximately 20% (1.1 million
inhabitants) of the Danish population lives. The Danish National
Health Service provides tax-supported health care to all residents
of the country and refunds part of patient expenditures for most
prescribed drugs, including antidepressants.
All health-related services are linked to individual patients
through their civil personal registration (CPR) number, assigned
by the Danish Civil Registration System to all Danish residents
since 1968. The CPR number encodes gender and date of birth and
facilitates accurate linkage between Danish registries, including the
Danish National Patient Registry (DNPR) and prescription
databases (Gaist et al, 1997; Sørensen et al, 2009).
We used the DNPR to identify all patients aged at least 35 years
whose first discharge diagnosis of CRC (ICD-8: 153.00–153.99,
154.00–154.19; ICD-10: C18.0–C18.9, C19.9, C20, and C20.9)
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yoccurred between 1 January 1991 and 31 December 2008 in North
Jutland County or between 1 January 1998 and 31 December 2008
in Aarhus County. The DNPR contains detailed individual-level
data on all non-psychiatric hospital admissions since 1977 and on
all outpatient hospital contacts since 1995. Immediately after
discharge from an inpatient hospitalisation or an outpatient clinic,
the DNPR records the patient’s CPR number, dates of admission
and discharge, and up to 20 discharge diagnoses (Andersen et al,
1999). To ensure availability of at least 2 years of prescription data
for each case, we included only CRC patients who resided in the
study area for at least 2 years before their diagnosis date, yielding a
total of 9979 CRC cases. The CRC diagnoses recorded in the DNPR
before 1991 for North Jutland and before 1998 for Aarhus County
were excluded from the study.
To identify controls, we accessed the Danish Civil Registration
System, which maintains electronic records of all changes in vital
status, migration, and residential address among Danish residents
(Frank, 2000; Pedersen et al, 2006). We selected 10 unique
population controls for each case, matched to cases on birth year,
gender, and residence (county through 2006 and region after 2006;
Sørensen et al, 2009), using risk-set sampling (Rothman et al,
2008). Risk-set sampling requires that controls be alive and at risk
of a first hospital admission for CRC at the time the corresponding
case was diagnosed. We assigned this date as the index date to both
the case and all of the case’s matched controls. We identified a
total of 99790 population controls, sampling only among
individuals who were residents of the study area for at least
2 years before the index date.
We ascertained use of antidepressants from the prescription
databases of two former Danish counties, North Jutland, and
Aarhus (as noted above, local governments were organised into
regions rather than counties in 2006). The North Jutland database
was established in 1989 (with complete coverage since 1991),
whereas that of Aarhus County was established in 1996 (with
complete coverage since 1998; Sørensen et al, 2009). Thus for
North Jutland, prescription data were available from 1 January
1989, whereas for Aarhus data were available from 1 January 1996.
Matching on residence assures no bias from the differences in time
periods with available prescription databases. Both databases
include the CPR number, the type and quantity (including tablet
and package sizes) of the prescribed drug according to the
Anatomical Therapeutic Chemical (ATC) classification system
(World Health Organisation Collaborating Centre for Drug
Statistics Methodology, 2001) and the date the prescription was
filled. We identified prescriptions for SSRIs, TCAs, and ‘other
antidepressants.’ The following preparations were available during
the study period: SSRIs: fluoxetine (N06AB03), citalopram
(N06AB04), paroxetine (N06AB05), sertraline (N06AB06), fluvo-
xamine (N06AB08), escitalopram (N06AB10); TCAs (non-geno-
toxic; van Schaik and Graf, 1991; van Schaik and Graf, 1993):
desipramine (N06AA01), imipramine (N06AA02), imipramine oxide
(N06AA03), clomipramine (N06AA04), opipramol (N06AA05),
trimipramine (N06AA06), doxepine (N06AA12), amoxapine
(N06AA17), lofepramine (N06AA07); TCAs (genotoxic; van Schaik
and Graf, 1991; van Schaik and Graf, 1993): amitriptyline
(N06AA09), nortriptyline (N06AA10), protriptyline (N06AA11),
dosulepine (N06AA16); and ‘other antidepressants’: maprotiline
(N06AA21 and N06AC01), mianserine (N06AX03), duloxetine
(N06AX), venlafaxine (N06AX16), mirtazapine (N06AX11), rebox-
etine (N06AX18), isocarboazide (N06AF01), and moclobemide
(N06AG02).
The prescription databases also provided information on use of
non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs) and
aspirin (ATC codes: M01A, N02BA01, N02BA51, and B01AC06;
Cuzick et al, 2009; Ulrich et al, 2006), statins (ATC codes:
C10AA01–C10AA07; Bonovas et al, 2007; Coogan et al, 2007; Singh
et al, 2009), drugs used to treat diabetes mellitus as a marker of the
disease (including insulin and oral hypoglycemics (ATC codes:
A10B and A10A; Larsson et al, 2005; Renehan and Shalet, 2005),
disulfiram as a proxy for chronic treated alcoholism (ATC code:
N07BB01 ; Giovannucci et al, 1995; Glynn et al, 1996), neuroleptics
(ATC code: N05A ; Dalton et al, 2006; Hippisley-Cox et al, 2007),
and post-menopausal hormone replacement therapy (HRT ; ATC
codes: G03C, G03D, G03F, and G03H B01; La Vecchia et al, 2005).
These drugs were chosen because of their reported associations
with CRC risk and potential associations with antidepressant use.
We obtained information from the DNPR on history of
inflammatory bowel disease, which can be associated both with
antidepressant treatment and with CRC (Mikocka-Walus et al,
2006); ulcerative colitis and Crohn’s disease (ICD-8 codes: 563.01,
563.19, and 569.04; ICD-10 codes: K50.0, K50.1, K50.8, K50.9, or
K51.0-K51.3). We also used the DNPR to identify previous hospital
diagnoses for alcoholism as a second proxy for heavy alcohol use
(ICD-8 code: 303; ICD-10 code: F10; Giovannucci et al, 1995; Glynn
et al, 1996).
We excluded antidepressant drug use in the year before CRC
diagnosis, to reduce the potential effect of undiagnosed disease on
drug use. We measured drug intensity in terms of the median
number of pills per day prescribed for each patient. We calculated
all other exposures (ever/never use and temporality) on the basis
of the total number of prescriptions filled during the exposure
period. Accordingly, we defined ‘ever users’ as persons with at
least two prescriptions during the entire exposure period and we
defined ‘never/rare users’ as those with fewer than two prescrip-
tions during the entire exposure period. To compare our drug
exposure assessment with that used in earlier studies (Coogan
et al, 2009; Haukka et al, 2010; Xu et al, 2006), we conducted a
sensitivity analysis categorising ever users of antidepressants as
persons with at least one antidepressant prescription.
We examined temporality of drug use by dividing ‘ever users’
into recent and former users. We defined recent users as those
who had at least two prescriptions filled in the period 1 to 2 years
before the index date and former users as those who had
fewer than two prescriptions filled 1 to 2 years before the index
date but at least two prescriptions filled during the entire
observation period.
We also examined whether intensity of drug use (number of pills
divided by the total duration of use) was associated with CRC risk.
Duration was defined as the number of days from the date of a first
prescription to the date of a last prescription plus the duration of
the last prescription. We calculated the duration of the last
prescription based on the prescription date and total number
of pills dispensed. We divided duration of drug use into short term
(1 year to o2 years), medium term (2 to 5 years) and long term
(at least 5 years). We multiplied intensity of drug use by 100 to
enable expression as a percentage. Categorisation of the intensity
of drug use differed by antidepressant type. We grouped intensity
of TCA use as low (o100%), medium (101–170%), and high
(4171%); intensity of SSRI use as low (o70%), medium (71–100%),
and high (4101%); and intensity of other antidepressant use as
low (o100%) and high (4101%). We based the intensity groups
on frequency of pills for each type of antidepressant. We further
divided TCAs into genotoxic and non-genotoxic categories
(van Schaik and Graf, 1991; van Schaik and Graf, 1993).
For potential confounding drugs, we categorised use as never/
rare, recent (1 to 2 years before diagnosis/index date), and former
use (at least 2 years before the diagnosis/index date). The
definition of never/rare use varied by medication. For NSAIDs,
statins, neuroleptics, and hormone replacement therapy, never/
rare use was considered less than two prescriptions throughout the
observation period. For aspirin, less than 100 pills were considered
never/rare use. We classified selective Cox-2 inhibitors and non-
aspirin NSAIDs together (ATC codes: M01A*) in a group called
‘NSAIDs,’ and put aspirin (ATC codes: B01AC06, N02BA01, and
N02BA51) into a separate group. For disulfiram, we considered
only never/ever use.
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We calculated the frequency and proportion of cases and controls in
categories of demographic variables, antidepressants use, potentially
confounding drugs, and potentially confounding diseases. In all
analyses, we used conditional logistic regression to compute odds
ratios (OR) and associated 95% confidence intervals (95% CI)
adjusted for the confounders discussed above. We used never or rare
use (less than two prescriptions in total) as the reference group.
In our sensitivity analyses, ever users were defined as those with
at least one antidepressant prescription. We carried out further
analyses to investigate the association of continuous use of
antidepressants with risk of CRC. We defined continuous use as
individuals who were prescribed at least two antidepressants each
year from the year of their first prescription to their last
prescription. Finally, we conducted separate analyses for the risk
of colon cancer and the risk of rectal cancer. Given the risk set
sampling of controls, the ORs provide estimates of the corre-
sponding incidence rate ratios in the underlying population.
Analyses were performed using SAS version 9.13 (SAS Institute
Inc., Cary, NC, USA).
RESULTS
Characteristics of the 9979 cases and 99790 population controls
are presented in Table 1. A slightly higher proportion of cases than
controls had a history of diabetes and alcoholism. A lower
proportion of cases than controls were recent users of NSAIDs,
statins, or HRT, or were ever users of neuroleptics. Tricyclic
antidepressants were used by 3.7% of cases and 4.0% of controls,
SSRIs by 8.5% of cases and 8.9% of controls, and other
antidepressants by 2.9% of cases and 3.1% of controls (Table 2).
Median age of the study population was 72.4 years.
Ever use of TCAs, SSRIs, or other antidepressants was not
notably associated with risk of CRC (OR¼0.94 (95% CI: 0.84,
1.05); OR¼0.97, (95% CI: 0.90, 1.05); and OR¼0.95 (95%
CI: 0.83, 1.07), respectively; Table 2). Associations for recent and
former use were also near the null. Analyses combining duration
and intensity of use also generated odds ratios near the null,
regardless of antidepressant type (Table 3). As some individuals
may have used drugs from all three classes, we repeated the
analysis with a single model that included variables representing
exposure to each drug group. There was little difference in the
odds ratios generated by this model (data not presented).
Individuals may also have switched from one antidepressant drug
type to another. We therefore carried out additional analyses
including individuals who used SSRI only, TCA only and both drug
types in a model. There was little change in the odds ratios
generated by this model (data not presented).
There was a slightly reduced risk of CRC associated with ever
use of non-genotoxic TCAs (OR¼0.88, 95% CI: 0.75, 1.04). Risk of
CRC was not associated with ever use of genotoxic TCAs
(OR¼0.99, 95% CI: 0.83, 1.18) or use of both types of TCAs
(OR¼1.00, 95% CI: 0.75, 1.33). Risk estimates by type of TCA were
all centred at the null for intensity, recency, and duration of use.
We found a slightly reduced risk of CRC associated with use of
TCAs (OR¼0.88, 95% CI: 0.73, 1.06) and SSRIs (OR¼0.88, 95%
CI: 0.75, 1.02) in our sensitivity analyses, with ever users defined as
individuals with at least one antidepressant prescription.
We saw no evidence of an association between continuous use of
antidepressants and CRC risk (data not presented).
DISCUSSION
Our findings show little evidence of a protective association
between antidepressant use and CRC risk, regardless of anti-
depressant type. The odds ratios were near null for both recent and
former use, and varied little by intensity and duration of use.
The validity of our estimates depends on several factors. We
identified our study population from continuously updated popula-
tion-based registries, with complete follow-up and high quality data.
For example, cancer diagnoses in the DNPR have high sensitivity and
specificity (Norgaard et al, 2005; Tetsche et al, 2005). Use of a
population-based prescription registry, whose completeness ap-
proaches 100% (Gaist et al, 1997), ensured unbiased assessment of
exposure before CRC diagnosis and eliminated recall bias. This
design also facilitated adjustment for potential confounding drugs,
diseases, and a more comprehensive list of potential confounders
than examined in some earlier studies. The design also allowed
assessment of a dose–response effect for antidepressant exposure in
terms of intensity and duration of drug use.
Although our study was immune to recall bias by design, non-
differential misclassification of antidepressant use was still an
Table 1 Frequency distribution of demographic factors, comorbidities,
and prescription medication use among colorectal cancer cases and
matched controls in Northern Denmark, 1991–2008. (number, %)
Cases Controls
N¼9979 % N¼99790 %
Gender
Women 4927 49 49270 49
Men 5052 51 50520 51
Diabetes
No 9210 92 93291 94
Yes 769 7.7 6499 6.5
Alcoholism
a
No 9719 97 97587 98
Yes 260 2.6 2203 2.2
Inflammatory bowel disease
No 9917 99 99253 100
Yes 62 0.6 537 0.5
NSAIDs
Never/rare use 6156 62 60146 60
Recent use (1–3 years) 2330 23 25187 25
Former use (3+ years) 1493 15 14457 15
Aspirin
b
Never/rare use 7846 79 77987 78
Recent use (1–3 years) 1892 19 19374 19
Former use (3+ years) 241 2.4 2429 2.4
Statins
Never/rare use 9268 93 92061 92
Recent use (1–3 years) 688 6.9 7499 7.5
Former use (3+ years) 23 0.2 230 0.2
Post-menopausal hormone replacement therapy
Never/rare use 8913 89 88190 88
Recent use (1–3 years) 708 7.1 7673 7.7
Former use (3+ years) 358 3.6 3927 3.9
Neuroleptics
Never/rare use 9424 94 93686 94
Recent use (1–3 years) 343 3.4 4043 4.1
Former use (3+ years) 212 2.1 2061 2.1
Marital status
Married 5649 57 56602 57
Never married 698 7.0 7202 7.2
Divorced or widowed 3632 36 35986 36
Abbreviation: NSAIDs¼non-steroidal anti-inflammatory drugs.
aThe definition of
alcoholism included prescriptions of disulfiram as a proxy for chronic alcohol abuse.
bLow- and high-dose aspirin were grouped together.
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yimportant limitation. Patients with depression are less likely to
comply with prescription medications than those without depres-
sion (DiMatteo et al, 2000). However, our drug exposure
assessment was based on redeemed prescriptions, for which
patients had to collect the prescription and pay a portion of the
drug cost. Our estimates are therefore likely to reflect actual use.
The SSRIs were introduced to the Danish market about 1987
(Olfson et al, 2002). The prescription registries were established in
1989 and 1996, so we were unable to identify individuals who may
have switched to SSRIs from TCAs before the study period.
Although we controlled for many confounders, we were unable to
adjust for body mass index, physical activity, or diet. We also had
no information on the indication for antidepressant use or the
severity of the underlying disease. Such confounding by indication
(i.e., severity of depression) would underestimate the impact of
antidepressant use on CRC risk. Of note, a large cohort study
found an increased risk of CRC among women with the highest
levels of depressive symptoms (Kroenke et al, 2005).
Our almost null results agree with the Finnish cohort study, which
also found no reduction in CRC risk associated with SSRI use
(Haukka et al, 2010). The Finnish study, however, did report a weak
association between increased risk of CRC and 44 years of TCA use,
which we did not observe. The Canadian also observed a slight
increase in risk of CRC with long-term use of TCA (16–20 years;
Coogan et al, 2009; Xu et al, 2006). We did not have such long-term
data. In addition, our results are not so inconsistent with the
Canadian and US studies, both of which reported a small reduction
in the risk of CRC associated with SSRI use (Coogan et al,2 0 0 9 ;X u
et al, 2006), but their CIs were quite broad and included the null.
Our previous experience with the prescription data indicated
quite a high prevalence of persons who fill just one antidepressant
prescription, which suggests that these persons may not have
completed taking even their first prescription. Therefore, to reduce
misclassification from this non-compliance, we defined ever users as
persons who had filled at least two prescriptions for antidepressants.
In a sensitivity analyses, we defined ever use as redemption of one
or more prescriptions instead of two or more prescriptions and
observed a slight decrease in associations between CRC occurrence
and antidepressant use more comparable with the results of the
earlier case–control studies (Coogan et al,2 0 0 9 ;X uet al, 2006).
This sensitivity analysis suggests that the definition of ever use (one
or more prescriptions) in the earlier studies contributed to the
decreased risk of CRC associated with antidepressant use.
We found no evidence of an association between use of
antidepressants and risk of colorectal cancer in this large
population-based study.
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Table 2 Ever/never use and temporality of antidepressant medication
use among colorectal cancer cases and matched controls in Northern
Denmark, 1991–2008 (number, %)
Cases Controls
N¼9979 % N¼99790 % OR
a 95% CI
Tricyclic antidepressants
Never/rare use 9614 96 95800 96 1.00
Ever use 365 3.7 3990 4.0 0.94 0.84, 1.05
Temporality of use
Never/rare use 9614 96 95800 96 1.00
Recent use
(0 to o2 years)
184 1.8 2029 2.0 0.93 0.80, 1.09
Former use
(2+ years)
181 1.8 1961 2.0 0.95 0.81, 1.11
Selective serotonin reuptake inhibitors
Never/rare use 9128 92 90900 91 1.00
Ever use 851 8.5 8890 8.9 0.97 0.90, 1.05
Temporality of use
Never/rare use 9128 92 90900 91 1.00
Recent use
(1 to o2 years)
540 5.4 6693 6.7 0.97 0.88, 1.07
Former use
(2+ years)
311 3.1 2197 2.2 0.97 0.86, 1.09
Other antidepressants
Never/rare use 9689 97 96654 97 1.00
Ever use 290 2.9 3136 3.1 0.95 0.83, 1.07
Temporality of use
Never/rare use 9689 97 96654 91 1.00
Recent use
(1 to o2 years)
188 1.9 2007 2.0 0.96 0.83, 1.12
Former use
(2+years)
102 1.0 1129 1.1 0.92 0.75, 1.13
Abbreviations: CI¼confidence interval; NSAIDs¼non-steroidal anti-inflammatory
drugs; OR¼odds ratio.
aAdjusted for diabetes, alcoholism, inflammatory bowel
disease, use of NSAIDs, use of statins, use of hormone replacement therapy, use of
aspirin, use of neuroleptics, and marital status.
Table 3 Duration and intensity of antidepressant medication use among
colorectal cancer cases and matched controls in Northern Denmark,
1991–2008 (number, %)
Cases Controls




Never/rare use 9614 96 95800 96 1.00
Low intensity 78 0.8 925 0.9 0.86 0.68, 1.09
Medium intensity 76 0.8 969 1.0 0.80 0.63, 1.01
High intensity 74 0.7 750 0.8 1.01 0.80, 1.29
Long-term use
Low intensity 51 0.5 524 0.5 1.00 0.75, 1.34
Medium intensity 33 0.3 349 0.4 0.98 0.69, 1.41
High intensity 53 0.5 473 0.5 1.17 0.88, 1.56
Selective serotonin reuptake inhibitors
Short-term use
Never/rare use 9128 91 90900 91 1.00
Low intensity 191 1.9 1865 1.9 1.04 0.89, 1.21
Medium intensity 216 2.2 2229 2.2 0.98 0.85, 1.13
High intensity 230 2.3 2599 2.6 0.90 0.78, 1.03
Long-term use
Low intensity 99 1.0 1075 1.1 0.94 0.76, 1.16
Medium intensity 62 0.6 648 0.7 0.97 0.74, 1.26
High intensity 53 0.5 474 0.5 1.13 0.85, 1.51
Other antidepressants
Short-term use
Never/rare use 9689 97 96654 97 1.00
Low intensity 109 1.1 1268 1.3 0.87 0.72, 1.07
High intensity 126 1.3 1212 1.2 1.07 0.88, 1.29
Long-term use
Low intensity 39 0.4 407 0.4 0.99 0.71, 1.38
High intensity 16 0.2 249 0.3 0.67 0.40, 1.11
Abbreviations: CI¼confidence interval; NSAIDs¼non-steroidal anti-inflammatory
drugs; OR¼odds ratio.
aAdjusted for diabetes, alcoholism, inflammatory bowel
disease, use of NSAIDs, use of statins, use of hormone replacement therapy, use of
low-dose aspirin and high-dose aspirin, use of neuroleptics, and marital status.
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